KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Research & Development (2016 - 2025)

Regeneron Pharmaceuticals has reported Research & Development over the past 17 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Research & Development at $1.6 billion for Q4 2025, up 15.15% from a year ago — trailing twelve months through Dec 2025 was $5.9 billion (up 13.99% YoY), and the annual figure for FY2025 was $5.9 billion, up 13.99%.
  • Research & Development for Q4 2025 was $1.6 billion at Regeneron Pharmaceuticals, up from $1.5 billion in the prior quarter.
  • Over the last five years, Research & Development for REGN hit a ceiling of $1.6 billion in Q4 2025 and a floor of $665.4 million in Q3 2021.
  • Median Research & Development over the past 5 years was $1.1 billion (2023), compared with a mean of $1.1 billion.
  • Peak annual rise in Research & Development hit 4661.33% in 2021, while the deepest fall reached 2.8% in 2021.
  • Regeneron Pharmaceuticals' Research & Development stood at $737.6 million in 2021, then soared by 41.42% to $1.0 billion in 2022, then increased by 12.86% to $1.2 billion in 2023, then grew by 19.95% to $1.4 billion in 2024, then grew by 15.15% to $1.6 billion in 2025.
  • The last three reported values for Research & Development were $1.6 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.